Poly Medicure Limited announced a scheduled one-on-one investor meeting with Axis Max Life for September 23, 2026. The virtual session is set for 4:00 pm, providing a platform for direct engagement between the company's officials and the investor.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III Part A. This regulatory framework mandates timely disclosure of material events and interactions with analysts or investors to ensure market transparency.

Meeting Details

The company confirmed that no unpublished price-sensitive information will be shared during the interaction. The schedule remains subject to change due to exigencies on the part of the analysts, investors, or the company itself.

Avinash Chandra, Company Secretary, signed the intimation filed with both the BSE and NSE listing departments. The full details are also available on the company's official website.

Medicure Inc. presented the design, rationale, and baseline data from its MEND-PNPO Phase 3 study at the 16th European Epilepsy Congress in Athens, Greece. The pivotal trial evaluates MC-1, a pharmaceutical-grade oral formulation of pyridoxal 5'-phosphate (P5P), for treating Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency.

The poster presentation, led by Dr. Phillip Pearl of Boston Children's Hospital and Harvard Medical School, outlines the study's primary and secondary endpoints, dosing regimens, and patient baseline metrics. Co-investigators from sites across the United States, Australia, and Europe contributed to the analysis.

Study Enrollment and Baseline Metrics

MEND-PNPO is a 52-week, open-label, multi-center, externally controlled study targeting patients aged 2 years and older with genetically confirmed PNPO deficiency. Enrollment commenced in January 2023 and is projected to conclude in 2026. The company aims to enroll approximately 10 patients in total.

As of the presentation, nine patients had been enrolled, with three completing the one-year study duration. Baseline data revealed significant variability in prior treatment regimens and physiological markers among participants.

PNPO deficiency is an ultra-rare inherited neurometabolic disorder caused by mutations in the PNPO gene. This mutation prevents adequate production of P5P, the active form of vitamin B6. The condition typically manifests in newborns and infants as severe, difficult-to-control seizures, potentially leading to developmental impairment, neurological dysfunction, or death if untreated. Lifelong P5P therapy is standard, yet no pharmaceutical-grade P5P product is currently approved.

What the Numbers Show

The wide disparity between baseline treatment regimens (14-58 mg/kg/day) and resulting steady-state P5P levels (59.8-165 ng/mL) highlights the clinical challenge of managing PNPO deficiency without standardized pharmaceutical-grade therapy. This variability underscores the rationale for MC-1, which seeks to provide consistent dosing and absorption compared to current non-pharmaceutical alternatives.

Forward-Looking Developments

Medicure plans to present the MEND-PNPO study at two additional North American conferences later this year. These include the Child Neurology Society Annual Meeting in Montreal, Canada, from October 14-17, 2026, and the American Epilepsy Society Annual Meeting in Denver, Colorado, from December 4-8, 2026.

Albert D. Friesen, President and CEO of Medicure, stated that presenting to the European epilepsy community builds awareness of the need for standardized P5P therapy. He emphasized the company's goal to bring the first approved therapy for PNPO deficiency to patients.

MC-1 is not FDA-approved, and its safety and effectiveness have not been established.